{"id":484047,"date":"2021-04-29T07:05:36","date_gmt":"2021-04-29T11:05:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-provides-first-quarter-2021-corporate-update\/"},"modified":"2021-04-29T07:05:36","modified_gmt":"2021-04-29T11:05:36","slug":"genocea-provides-first-quarter-2021-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-provides-first-quarter-2021-corporate-update\/","title":{"rendered":"Genocea Provides First Quarter 2021 Corporate Update"},"content":{"rendered":"
\n

\n
\n GEN-011 and GEN-009 immuno-oncology programs continue to advance<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Research on Inhibigens<\/em>
\n <\/strong>
\n \u2122<\/strong>
\n
\n and SARS-CoV-2 continues to progress <\/em>
\n <\/strong>\n <\/p>\n

\n
\n Conference call today at 8:30 a.m. E.T.<\/em>
\n <\/strong>\n <\/p>\n

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc.<\/a> (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the first quarter ended March 31, 2021.<\/p>\n

\u201cGenocea continues to accumulate evidence that our ATLAS\u2122 platform may enable immunotherapies that preferentially attack the surface-presented antigens driving anti-tumor responses or as we say, \u2018Targets Matter\u2019,\u201d said Chip Clark, Genocea\u2019s President and Chief Executive Officer. \u201cWhether through our ongoing clinical trials with GEN-011, our neoantigen-targeted peripheral T cell (\u201cNPT\u201d) therapy and GEN-009, our neoantigen vaccine, or through our research efforts with Inhibigens\u2122 and SARS-CoV-2 antigen discovery, we look forward to providing updates consistent with this thesis throughout the year.\u201d<\/p>\n

\n Clinical updates<\/strong>
\n
\n GEN-011 Phase 1\/2a clinical trial (the \u201cTITAN study\u201d)<\/em>\n <\/p>\n